Redoxis

Executive Summary

Redoxis is a Swedish contract research organization (CRO) specializing in preclinical drug development and efficacy evaluation using models of autoimmune diseases. Founded in 2009 and rooted in academic research, the company continuously updates its portfolio of disease models to meet evolving drug development needs. Its expertise spans multiple autoimmune indications, enabling pharma and biotech clients to validate therapeutic candidates in relevant in vivo systems. As a privately held, pre-clinical stage company, Redoxis operates from its headquarters in Gothenburg, Sweden, and serves a global client base seeking reliable, translational data to advance their pipelines. The rising prevalence of autoimmune disorders and increasing R&D outsourcing trends position Redoxis favorably for growth. Its academic pedigree and model innovation provide a competitive edge in a fragmented CRO market. While financial details are undisclosed, the company's sustained operation since 2009 suggests stable client relationships and recurring revenue. Key growth drivers include expansion of model offerings, strategic partnerships, and geographic reach. However, as a small CRO, it faces competition from larger players and potential dependency on a few key clients. Overall, Redoxis represents a niche, asset-light opportunity in autoimmune drug development support.

Upcoming Catalysts (preview)

• TBDLaunch of novel autoimmune disease models (e.g., lupus, multiple sclerosis)70% success
• TBDStrategic partnership or service agreement with a top pharma company50% success
• TBDExpansion into new geographic markets (e.g., North America, Asia)40% success